SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
NOVEL TREATMENTS FOR SARS-CoV-2: STARTING AT THE BENCH
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
A NOVEL COVID-19 CURE STRATEGY: HIJACKING SARS-COV-2 RNA-DEPENDENT RNA POLYMERASE (ABSTRACT
381)
Serhat Gumrukcu
Seraph Research Institute, Los Angeles, CA, USA
NOVEL ENTRY INHIBITORS AGAINST SARS-COV-2 BASED ON INTERFACE OF SPIKE RBD (ABSTRACT
382)
Arpan Acharya
University of Nebraska Medical Center, Omaha, NE, USA
RATIONALLY DESIGNED ACE2-DERIVED PEPTIDES INHIBIT SARS-COV-2 (ABSTRACT
383)
Amit Sharma
Ohio State University, Columbus, OH, USA
RNHC INHIBITS SARS-COV-2 IN VITRO BUT IS MUTAGENIC IN MAMMALIAN CELLS (ABSTRACT
384)
Shuntai Zhou
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
ANTI–SARS-COV-2 MULTI-DOMAIN DARPIN® MOLECULES AS HIGHLY POTENT THERAPEUTICS (ABSTRACT
385)
Michael Tobias Stumpp
Molecular Partners, Zürich, Switzerland
IDENTIFICATION OF REPURPOSING DRUGS AGAINST SARS-COV-2 USING HUMAN LUNG TISSUES (ABSTRACT
386)
Judith Grau-Expósito
Vall d'Hebron Research Institute, Barcelona, Spain
THE 3CLPRO INHIBITOR ALG-097111 POTENTLY INHIBITS SARS-COV-2 REPLICATION IN HAMSTERS (ABSTRACT
387)
Koen Vandyck
Aligos, Leuven, Not US or Canada, Belgium
A SARS-COV-2–NEUTRALIZING ACE2 DECOY SHOWS HIGH AFFINITY FOR N501Y AND L452R VARIANTS (ABSTRACT
388)
Shiho Tanaka
ImmunityBio, Culver City, CA, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
